Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.58 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | EFNA1 | P20827 | 1/20 | 0.58 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.58 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.58 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.58 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.58 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.58 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.58 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.58 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | GABRP | O00591 | 4/20 | 0.54 |
| ▸ | GABRD | O14764 | 4/20 | 0.54 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.54 |
| ▸ | GABRB1 | P18505 | 4/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL497658 | 1.00 | MEN1 (0.58) | MEN1KMT2AAKR1B10AKR1B1LMNA | |
| SCHEMBL497657 | 1.00 | MEN1 (0.58) | MEN1KMT2AAKR1B10AKR1B1LMNA | |
| SCHEMBL13988189 | 1.00 | MEN1 (0.58) | MEN1KMT2AAKR1B10AKR1B1LMNA | |
| SCHEMBL11060164 | 1.00 | MEN1 (0.58) | MEN1KMT2AAKR1B10AKR1B1LMNA | |
| SCHEMBL11345742 | 1.00 | MEN1 (0.58) | MEN1KMT2AAKR1B10AKR1B1LMNA | |
| SCHEMBL6044996 | 1.00 | MEN1 (0.58) | MEN1KMT2AAKR1B10AKR1B1LMNA | |
| SCHEMBL11696291 | 0.90 | MEN1 (0.57) | MEN1KMT2AAKR1B10AKR1B1LMNA | |
| Acetic Acid SCHEMBL29519885 | 0.89 | GABRP (0.66) | MEN1KMT2AAKR1B10AKR1B1LMNA | |
| SCHEMBL23872369 | 0.89 | GABRA1 (0.69) | MEN1KMT2AAKR1B10AKR1B1LMNA | |
| SCHEMBL598324 | 0.89 | GABRA1 (0.69) | MEN1KMT2AAKR1B10AKR1B1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4885280-A | CARDIOTONIC AGENTS | NORWICH EATON PHARMACEUTICALS, INC. (US) | 1989-12-05 | — | — | US | claimed |
| JP-1156995-A | — | — | None | — | — | JP | disclosed |
| US-20060025393-A1 | Steroid derivatives | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-02-02 | — | — | US | disclosed |
| US-20040152681-A1 | Steroid derivatives | ARCH DEVELOPMENT CORPORATION, AN ILLINOIS CORPORATION | 2004-08-05 | — | — | US | disclosed |
| US-6645955-B1 | Nuclear liver X receptor (LXR) and ubiquitous receptor (UR) disorders; cancer, rheumatic arthritis, diabetes, Alzheimer*s disease | ARCH DEVELOPMENT CORPORATION | 2003-11-11 | — | — | US | disclosed |
| EP-1189922-A4 | STEROID DERIVATIVES | ARCH DEV CORP (US) | 2002-08-14 | — | — | EP | disclosed |
| EP-1189922-A1 | STEROID DERIVATIVES | Arch Development Corporation (US) | 2002-03-27 | — | — | EP | disclosed |
| WO-2000066611-A1 | STEROID DERIVATIVES | ARCH DEVELOPMENT CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
| EP-0721459-B1 | NOVEL OLIGOSACCHARIDE-CONTAINING 14-AMINOSTEROID COMPOUNDS AND NOVEL DIASTEREOSELECTIVE AMINOSTEROID PROCESS CHEMISTRY | PROCTER & GAMBLE (US) | 2000-05-31 | — | — | EP | disclosed |
| US-5710259-A | TREATING CONGESTIVE HEART FAILURE | THE PROCTER & GAMBLE COMPANY (US) | 1998-01-20 | — | — | US | disclosed |
| EP-0720616-A1 | NOVEL DEOXY AND OXYGEN-SUBSTITUTED SUGAR-CONTAINING 14-AMINOSTEROID COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 1996-07-10 | — | — | EP | disclosed |
| WO-1995008558-A1 | NOVEL DEOXY AND OXYGEN-SUBSTITUTED SUGAR-CONTAINING 14-AMINOSTEROID COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 1995-03-30 | — | — | WO | disclosed |
| US-4885280-A | CARDIOTONIC AGENTS | NORWICH EATON PHARMACEUTICALS, INC. (US) | 1989-12-05 | — | — | US | disclosed |
| EP-0155096-B1 | 17 BETA-SUBSTITUTED-4-AZA-5-ALPHA-ANDROSTENONES AND THEIR USE AS 5-ALPHA-REDUCTASE INHIBITORS | MERCK & CO. INC. (US) | 1989-10-04 | — | — | EP | disclosed |
| JP-H01156995-A | NEW ANDROSTANE 17-CARBOXYLIC ACID ESTER, ITS PREPARATION AND PHARMACEUTIC CONTAINING THAT | NORWICH EATON PHARMACEUT INC | 1989-06-20 | — | — | JP | disclosed |
| EP-0285383-A2 | Treatment of prostatic carcinoma with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones | MERCK & CO. INC. (US) | 1988-10-05 | — | — | EP | disclosed |
| EP-0285382-A2 | Treatment of androgenic alopecia with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones | MERCK & CO. INC. (US) | 1988-10-05 | — | — | EP | disclosed |
| US-4460509-A | STEROIDS WITH HETERO RING SIDE CHAIN | BETH ISRAEL MEDICAL CENTER (US) | 1984-07-17 | — | — | US | disclosed |
| US-4335121-A | TOPICAL ANTIINFLAMMATORY AGENTS | GLAXO GROUP LIMITED (GB) | 1982-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025393-A1 | Steroid derivatives | NR5A1, NR3C2, NR3C1 | MEN1 451/4885KMT2A 2718/4885AKR1B10 467/4885 |
| US-20040152681-A1 | Steroid derivatives | NR1H3, NR1H2, NR1H4 | MEN1 4600/4885KMT2A 3338/4885AKR1B10 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.